{"schema_version":"secwatch.filing_event.v1","accession":"0000078003-24-000017","form_type":"8-K","ticker":"PFE","cik":"0000078003","company_name":"PFIZER INC","filed_at":"2024-01-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.907283+00:00","generated_at":"2026-06-06T15:27:38.281465+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Pfizer posts FY2023 revenue $58.5B, adj EPS $1.84; reaffirms FY2024 guidance","bullets":["Full-year 2023 revenues $58.5B, down 41% operationally; reported diluted EPS $0.37, down 93%; adjusted diluted EPS $1.84, down 72%.","Q4 2023 revenues $14.2B, down 42% operationally; reported diluted LPS $(0.60), adjusted EPS $0.10.","Ex-COVID products grew 7% operationally in FY2023 (8% in Q4); Seagen acquisition closed Dec 2023 for $44B.","FY2024 revenue guidance $58.5-61.5B, adj EPS $2.05-2.25; expects $4B cost savings by end 2024.","No share repurchases planned in 2024; $9.2B dividends paid in FY2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000078003-24-000017","json":"https://secwatch.observer/filing/0000078003-24-000017.json","markdown":"https://secwatch.observer/filing/0000078003-24-000017.md","text":"https://secwatch.observer/filing/0000078003-24-000017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/78003/000007800324000017/0000078003-24-000017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/78003/000007800324000017/pfe-20240130.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T15:27:38.281465+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"036607f476c6ab1ed62a81eb46fdf199b30e340d","claim":"PFIZER INC reported full-year 2024 results: revenue $58.5 to $61.5 Billion, EPS $2.05 to $2.25. Guidance reaffirmed.","evidence_excerpt":"Annual Net Cost Savings by End of 2024 from Previously Announced Cost Realignment Program ▪ Reaffirms Full-Year 2024 Guidance (5) Provided on December 13, 2023, of Revenues of $58.5 to $61.5 Billion and Adjusted (3) Diluted EPS of $2.05 to $2.25 NEW YORK, Tuesday, January 30, 2024 — Pfizer Inc. (NYSE: PFE) reported financial results for fourth quarter and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/78003/000007800324000017/0000078003-24-000017-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full-year 2024"},{"label":"Revenue","value":"$58.5 to $61.5 Billion"},{"label":"EPS","value":"$2.05 to $2.25"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"1e03e19483a491aca922e5cb68ee7f512362305a","claim":"PFIZER INC reported fourth-quarter 2023 results: revenue $14.2 Billion, net income ($3,369) million, EPS ($0.60).","evidence_excerpt":"$0.37, Down 93% Year-Over-Year, and Adjusted (3) Diluted EPS of $1.84, Down 72% Year-Over-Year, Significantly Impacted by One-Time Events (4) ▪ Fourth-Quarter 2023 Revenues of $14.2 Billion – Expected Decline in Comirnaty (1) and Paxlovid Revenues Drove 42% Operational Decrease in Fourth-Quarter Revenues – Excluding Contributions from Comirnaty (1) and Paxlovid,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/78003/000007800324000017/0000078003-24-000017-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth-quarter 2023"},{"label":"Revenue","value":"$14.2 Billion"},{"label":"Net income","value":"($3,369) million"},{"label":"EPS","value":"($0.60)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"4647c4c0bcbc0ebc70c53d07a37e22a1b0eb2568","claim":"PFIZER INC reported full-year 2023 results: revenue $58.5 Billion, net income $2,119 million, EPS $0.37.","evidence_excerpt":"Launched Significant Number of New Products and Indications; and Realigned Commercial Organization to Improve Focus, Speed and Execution ▪ Full-Year 2023 Revenues of $58.5 Billion – Expected Decline in Comirnaty (1) and Paxlovid Revenues Drove 41% Operational Decrease in Year-Over-Year Revenues – Excluding Contributions from Comirnaty (1) and Paxlovid,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/78003/000007800324000017/0000078003-24-000017-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full-year 2023"},{"label":"Revenue","value":"$58.5 Billion"},{"label":"Net income","value":"$2,119 million"},{"label":"EPS","value":"$0.37"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}